Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
Porter DP, Kulkarni R, Fralich T, Miller MD, White KL. Porter DP, et al. Among authors: miller md. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26. doi: 10.1097/QAI.0000000000000017. J Acquir Immune Defic Syndr. 2014. PMID: 24525469 Clinical Trial.
Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
Andreatta K, Kulkarni R, Abram ME, Nguyen T, Cao H, Miller MD, White KL. Andreatta K, et al. Among authors: miller md. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):519-26. doi: 10.1097/QAI.0000000000000503. J Acquir Immune Defic Syndr. 2015. PMID: 25559592
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
Andreatta KN, Miller MD, White KL. Andreatta KN, et al. Among authors: miller md. Antimicrob Agents Chemother. 2015 Nov 16;60(2):757-65. doi: 10.1128/AAC.02096-15. Print 2016 Feb. Antimicrob Agents Chemother. 2015. PMID: 26574015 Free PMC article.
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
Porter DP, Toma J, Tan Y, Solberg O, Cai S, Kulkarni R, Andreatta K, Lie Y, Chuck SK, Palella F, Miller MD, White KL. Porter DP, et al. Among authors: miller md. HIV Clin Trials. 2016 Feb;17(1):29-37. doi: 10.1080/15284336.2015.1115585. HIV Clin Trials. 2016. PMID: 26899540 Clinical Trial.
1,111 results